[1] Zhou B, Westaway S K, Levinson B, Johnson M A, Gitschier J, Hayflick S J. A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome . Nat Genet, 2001, 28(4): 345-9.
[2] Razmeh S, Habibi A H, Orooji M, Alizadeh E, Moradiankokhdan K, Razmeh B. Pantothenate kinase-associated neurodegeneration: Clinical aspects, diagnosis and treatments. Neurol Int, 2018, 10(1): 7516.
[3] Hayflick S J, Westaway S K, Levinson B, Zhou B, Johnson M A, Ching K H, Gitschier J. Genetic, clinical, and radiographic delineation of Hallervorden–Spatz syndrome. New Engl J Med, 2003, 348(1): 33-40.
[4] Kurian M A, Hayflick S J. Pantothenate kinase-associated neurodegeneration (PKAN) and PLA2G6-associated neurodegeneration (PLAN): review of two major neurodegeneration with brain iron accumulation (NBIA) phenotypes. Int Rev Neurobiol, 2013, 110:49-71.
[5] Brezavar D, Bonnen P E. Incidence of PKAN determined by bioinformatic and population-based analysis of ~140,000 humans. Mol Genet Genomics, 2019, 128(4): 463-9.
[6] Rana A, Seinen E, Siudeja K, Muntendam R, Srinivasan B, Van Der Want J J, Hayflick S, Reijngoud D-J, Kayser O, Sibon O C. Pantethine rescues a Drosophila model for pantothenate kinase–associated neurodegeneration. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107(15): 6988-93.
[7] Brunetti D, Dusi S, Giordano C, Lamperti C, Morbin M, Fugnanesi V, Marchet S, Fagiolari G, Sibon O, Moggio M, D'amati G, Tiranti V. Pantethine treatment is effective in recovering the disease phenotype induced by ketogenic diet in a pantothenate kinase-associated neurodegeneration mouse model. Brain, 2014, 137(Pt 1): 57-68.
[8] Wittwer C T, Gahl W A, Butler J D, Zatz M, Thoene J G. Metabolism of pantethine in cystinosis. J Clin Invest, 1985, 76(4): 1665-72.
[9] De Vloo P, Lee D J, Dallapiazza R F, Rohani M, Fasano A, Munhoz R P, Ibrahim G M, Hodaie M, Lozano A M, Kalia S K. Deep brain stimulation for pantothenate kinase‐associated neurodegeneration: A meta‐analysis. Mov Disord, 2019, 34(2): 264-73.
[10] Svetel M, Tomic A, Dragasevic N, Petrovic I, Kresojevic N, Jech R, Urgosik D, Banjac I, Vitkovic J, Novakovic I. Clinical course of patients with pantothenate kinase-associated neurodegeneration (PKAN) before and after DBS surgery. J Neurol, 2019, 266(12): 2962-9.
[11] Klopstock T, Tricta F, Neumayr L, Karin I, Zorzi G, Fradette C, Kmiec T, Buchner B, Steele H E, Horvath R. Safety and efficacy of deferiprone for pantothenate kinase-associated neurodegeneration: a randomised, double-blind, controlled trial and an open-label extension study. Lancet Neurol, 2019, 18(7): 631-42.
[12] Christou Y P, Tanteles G A, Kkolou E, Ormiston A, Konstantopoulos K, Beconi M, Marshall R D, Plotkin H, Kleopa K A. Open-Label Fosmetpantotenate, a Phosphopantothenate Replacement Therapy in a Single Patient with Atypical PKAN . Case Rep Neurol Med, 2017, 2017:3247034.
[13] Sharma L K, Subramanian C, Yun M, Frank M W, White S W, Rock C O, Lee R E, Jackowski S. A therapeutic approach to pantothenate kinase associated neurodegeneration. Nature Communications, 2018, 9(1): 4399.
[14] Brunetti D, Dusi S, Morbin M, Uggetti A, Moda F, D'amato I, Giordano C, D'amati G, Cozzi A, Levi S. Pantothenate kinase-associated neurodegeneration: altered mitochondria membrane potential and defective respiration in Pank2 knock-out mouse model. Human molecular genetics, 2012, 21(24): 5294-305.
[15] Jackowski S. Proposed Therapies for Pantothenate-Kinase-Associated Neurodegeneration . J Exp Neurosci, 2019, 13:117906951985111.
[16] Jeong S Y, Hogarth P, Placzek A, Gregory A M, Fox R, Zhen D, Hamada J, Van Der Zwaag M, Lambrechts R, Jin H, Nilsen A, Cobb J, Pham T, Gray N, Ralle M, Duffy M, Schwanemann L, Rai P, Freed A, Wakeman K, Woltjer R L, Sibon O C, Hayflick S J. 4'-Phosphopantetheine corrects CoA, iron, and dopamine metabolic defects in mammalian models of PKAN. EMBO Mol Med, 2019, 11(12): e10489.